{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T13:57:14Z","timestamp":1776347834713,"version":"3.51.2"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007950","name":"Tanta University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007950","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This study evaluated the antitumor efficacy of atorvastatin (ATO) and luteolin (LUT), administered individually or in combination with or without doxorubicin (DOX), in mice bearing solid Ehrlich carcinoma (SEC). Additionally, we examined the effects of these treatments on ATP-binding cassette (ABC) transporters, telomerase reverse transcriptase (TERT), and cancer stem cell\u2013related markers as potential mechanisms underlying chemoresistance. SEC tumors were induced in 70 Swiss albino female mice, which were randomly assigned into seven groups (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200910\/group): SEC control, DOX (4\u00a0mg\/kg, i.p.), ATO (20\u00a0mg\/kg, i.p.), LUT (40\u00a0mg\/kg, i.p.), ATO+\u2009DOX, LUT+DOX, and ATO\u2009+\u2009LUT. At the end of the study, tumors were excised, weighed, and processed for histopathological evaluation, immunohistochemical analysis of CD44, quantitative assessment of ABCB1 and ABCG2 gene expression, and protein analysis of both the non-phosphorylated (TERT) and phosphorylated form (P-TERT). Co-treated groups exhibited a greater reduction in tumor growth compared to the control and single-agent groups. These effects were accompanied by marked downregulation of ABCB1 and ABCG2 gene expression and suppression of TERT and P-TERT protein levels. Histopathological findings revealed increased apoptotic features, including karyorrhexis, and reduced mitotic activity in the co-treated groups. CD44 immunostaining was strong in the SEC and DOX groups, moderate in the ATO- or LUT-treated groups, and weak in the co-treated groups. Combining ATO or LUT with DOX enhanced antitumor efficacy and attenuated molecular determinants associated with chemoresistance in SEC. Notably, the ATO+\u2009LUT combination without DOX demonstrated the greatest antitumor efficacy compared to DOX-containing regimens, highlighting its potential as a multi-target, non-cytotoxic therapeutic strategy.\n                  <\/jats:p>","DOI":"10.1007\/s12032-026-03257-y","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T10:58:27Z","timestamp":1774004307000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enhanced antitumor activity of atorvastatin and luteolin, with or without doxorubicin, in a solid Ehrlich carcinoma mouse model: modulation of ABC transporters, telomerase, and cancer stem cells"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2225-1671","authenticated-orcid":false,"given":"Ghada M.","family":"Al-Ashmawy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0908-8147","authenticated-orcid":false,"given":"Nahla E.","family":"El-Ashmawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1106-4072","authenticated-orcid":false,"given":"Omnia B.","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4539-8940","authenticated-orcid":false,"given":"Naglaa F.","family":"Khedr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"3257_CR1","doi-asserted-by":"publisher","first-page":"312","DOI":"10.62877\/35-ijcbs-24-25-19-35","volume":"25","author":"MI El Dosoky","year":"2024","unstructured":"El Dosoky MI, Fadel SM, Mohamed MASAM. Epidemiology, risk factors and molecular subtypes of Breast Carcinoma. Int J Chem Biochem Sci. 2024;25:312\u20137. https:\/\/doi.org\/10.62877\/35-ijcbs-24-25-19-35.","journal-title":"Int J Chem Biochem Sci"},{"key":"3257_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.265","volume":"4","author":"ZN Lei","year":"2023","unstructured":"Lei ZN, Tian Q, Teng QX, Wurpel JN, Zeng L, Pan Y, et al. Understanding and targeting resistance mechanisms in cancer. MedComm. 2023;4:e265. https:\/\/doi.org\/10.1002\/mco2.265.","journal-title":"MedComm"},{"key":"3257_CR3","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1080\/1061186x.2022.2091578","volume":"30","author":"A Modi","year":"2022","unstructured":"Modi A, Roy D, Sharma S, Vishnoi JR, Pareek P, Elhence P, Sharma P, Purohit P. ABC transporters in breast cancer: their roles in multidrug resistance and beyond. J Drug Target. 2022;30:927\u201347. https:\/\/doi.org\/10.1080\/1061186x.2022.2091578.","journal-title":"J Drug Target"},{"key":"3257_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22063199","volume":"22","author":"J He","year":"2021","unstructured":"He J, Fortunati E, Liu D-X, Li Y. Pleiotropic roles of ABC transporters in breast cancer. Int J Mol Sci. 2021;22:3199. https:\/\/doi.org\/10.3390\/ijms22063199.","journal-title":"Int J Mol Sci"},{"key":"3257_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-03041-2","volume":"23","author":"JH Ali","year":"2023","unstructured":"Ali JH, Walter M. Combining old and new concepts in targeting telomerase for cancer therapy: transient, immediate, complete and combinatory attack (TICCA). Cancer Cell Int. 2023;23:197. https:\/\/doi.org\/10.1186\/s12935-023-03041-2.","journal-title":"Cancer Cell Int"},{"key":"3257_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cells10040867","volume":"10","author":"A Romaniuk-Drapa\u0142a","year":"2021","unstructured":"Romaniuk-Drapa\u0142a A, Toto\u0144 E, Konieczna N, Machnik M, Barczak W, Kowal D, et al. hTERT downregulation attenuates resistance to DOX, impairs FAK-mediated adhesion, and leads to autophagy induction in breast cancer cells. Cells. 2021;10:867. https:\/\/doi.org\/10.3390\/cells10040867.","journal-title":"Cells"},{"issue":"1","key":"3257_CR7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41419-024-06454-7","volume":"15","author":"M Liu","year":"2024","unstructured":"Liu M, Zhang Y, Jian Y, Gu L, Zhang D, Zhou H, et al. The regulations of telomerase reverse transcriptase (TERT) in cancer. Cell Death Dis. 2024;15:90. https:\/\/doi.org\/10.1038\/s41419-024-06454-7.","journal-title":"Cell Death Dis"},{"key":"3257_CR8","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.tem.2022.02.002","volume":"33","author":"X Weng","year":"2022","unstructured":"Weng X, Maxwell-Warburton S, Hasib A, Ma L, Kang L. The membrane receptor CD44: novel insights into metabolism. Trends Endocrinol Metab. 2022;33:318\u201332. https:\/\/doi.org\/10.1016\/j.tem.2022.02.002.","journal-title":"Trends Endocrinol Metab"},{"key":"3257_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.554","volume":"5","author":"Y Xu","year":"2024","unstructured":"Xu Y, Bai Z, Lan T, Fu C, Cheng P. CD44 and its implication in neoplastic diseases. CD44 and its implication in neoplastic diseases. MedComm. 2024;5:e554. https:\/\/doi.org\/10.1002\/mco2.554.","journal-title":"MedComm"},{"key":"3257_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01867-y","volume":"22","author":"Y Mai","year":"2023","unstructured":"Mai Y, Su J, Yang C, Xia C, Fu L. The strategies to cure cancer patients by eradicating cancer stem-like cells. Mol Cancer. 2023;22:171. https:\/\/doi.org\/10.1186\/s12943-023-01867-y.","journal-title":"Mol Cancer"},{"key":"3257_CR11","doi-asserted-by":"publisher","first-page":"7970","DOI":"10.1111\/febs.16179","volume":"289","author":"Q Guo","year":"2022","unstructured":"Guo Q, Yang C, Gao F. The state of CD44 activation in cancer progression and therapeutic targeting. FEBS J. 2022;289:7970\u201386.","journal-title":"FEBS J"},{"key":"3257_CR12","doi-asserted-by":"publisher","DOI":"10.21037\/tbcr-23-32","volume":"4","author":"DR Radulski","year":"2023","unstructured":"Radulski DR, Stipp MC, Galindo CM, Acco A. Features and applications of Ehrlich tumor model in cancer studies: a literature review. Transl Breast Cancer Res. 2023;4:22. https:\/\/doi.org\/10.21037\/tbcr-23-32.","journal-title":"Transl Breast Cancer Res"},{"key":"3257_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.21608\/jcvr.2022.240866","volume":"4","author":"N Saleh","year":"2022","unstructured":"Saleh N, Allam T, Abdelfattah A, El-Borai N. Review on Ehrlich ascites carcinoma in mice and cancer treatment with special reference to the potential protective and therapeutic effects of hesperidin versus cisplatin. JCVR. 2022;4:47\u201357. https:\/\/doi.org\/10.21608\/jcvr.2022.240866.","journal-title":"JCVR"},{"key":"3257_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cells12040659","volume":"12","author":"M Kciuk","year":"2023","unstructured":"Kciuk M, Gieleci\u0144ska A, Mujwar S, Ko\u0142at D, Ka\u0142uzi\u0144ska-Ko\u0142at \u017b, Celik I, et al. Doxorubicin\u2014an agent with multiple mechanisms of anticancer activity. Cells. 2023;12:659. https:\/\/doi.org\/10.3390\/cells12040659.","journal-title":"Cells"},{"key":"3257_CR15","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.31557\/apjcp.2021.22.4.1095","volume":"22","author":"IH El-Khashab","year":"2021","unstructured":"El-Khashab IH. Antiangiogenic and proapoptotic activities of atorvastatin and ganoderma lucidum in tumor mouse model via VEGF and caspase-3 pathways. Asian Pac J Cancer Prev. 2021;22:1095\u2013104. https:\/\/doi.org\/10.31557\/apjcp.2021.22.4.1095.","journal-title":"Asian Pac J Cancer Prev"},{"key":"3257_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-022-01892-9","volume":"40","author":"Z Shaghaghi","year":"2022","unstructured":"Shaghaghi Z, Alvandi M, Farzipour S, Dehbanpour MR, Nosrati S. A review of effects of atorvastatin in cancer therapy. Med Oncol. 2022;40:27. https:\/\/doi.org\/10.1007\/s12032-022-01892-9.","journal-title":"Med Oncol"},{"key":"3257_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2024.151078","volume":"742","author":"KS El-Said","year":"2025","unstructured":"El-Said KS, Attia MS, Abdelmoaty BE, Salim EI. Synergistic antitumor effects of atorvastatin and chemotherapies: in vitro and in vivo studies. Biochem Biophys Res Commun. 2025;742:151078. https:\/\/doi.org\/10.1016\/j.bbrc.2024.151078.","journal-title":"Biochem Biophys Res Commun"},{"key":"3257_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-25040-1","volume":"15","author":"Y Meng","year":"2025","unstructured":"Meng Y, Mo L, Liang T, Mo S, Han C, He Y. Atorvastatin negatively regulates MAPK pathway in vitro to inhibit proliferation, migration, and invasion of hepatocellular carcinoma cells. Sci Rep. 2025;15:41279. https:\/\/doi.org\/10.1038\/s41598-025-25040-1.","journal-title":"Sci Rep"},{"key":"3257_CR19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.4196\/kjpp.2022.26.5.367","volume":"26","author":"YS Choi","year":"2022","unstructured":"Choi YS, Cho HJ, Jung HJ. Atorvastatin inhibits the proliferation of MKN45-derived gastric cancer stem cells in a mevalonate pathway-independent manner. Korean J Physiol Pharmacol. 2022;26:367\u201375. https:\/\/doi.org\/10.4196\/kjpp.2022.26.5.367.","journal-title":"Korean J Physiol Pharmacol"},{"key":"3257_CR20","doi-asserted-by":"publisher","first-page":"350","DOI":"10.4111\/icu.20210411","volume":"63","author":"Z Zhu","year":"2022","unstructured":"Zhu Z, Cao Y, Liu L, Zhao Z, Yin H, Wang H. Atorvastatin regulates the migration and invasion of prostate cancer through the epithelial-mesenchymal transformation and matrix metalloproteinase pathways. Investig Clin Urol. 2022;63:350\u20138. https:\/\/doi.org\/10.4111\/icu.20210411.","journal-title":"Investig Clin Urol"},{"key":"3257_CR21","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1002\/mc.23494","volume":"62","author":"Z Deza","year":"2023","unstructured":"Deza Z, Caimi GR, Noelia M, Coli L, Ridruejo E, Alvarez L. Atorvastatin shows antitumor effect in hepatocellular carcinoma development by inhibiting angiogenesis via TGF-\u03b21\/pERK signaling pathway. Mol Carcinog. 2023;62:398\u2013407. https:\/\/doi.org\/10.1002\/mc.23494.","journal-title":"Mol Carcinog"},{"key":"3257_CR22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.30574\/gscbps.2024.29.3.0457","volume":"29","author":"S Maryam","year":"2024","unstructured":"Maryam S, Khalid S, Arshad A, Abid S, Iqbal LZ, Amjad Y, et al. Luteolin: a versatile flavonoid for anti-inflammatory, anti-cancer, and neuroprotective therapies. GSC Biol Pharm Sci. 2024;29:119\u201337. https:\/\/doi.org\/10.30574\/gscbps.2024.29.3.0457.","journal-title":"GSC Biol Pharm Sci"},{"key":"3257_CR23","doi-asserted-by":"publisher","unstructured":"Aljohani H, Khodier AE, Al-Gayyar MM, Khodier A. Antitumor activity of Luteolin against Ehrlich solid carcinoma in rats via blocking Wnt\/\u03b2-catenin\/Smad4 pathway. Cureus. 2023;15. https:\/\/doi.org\/10.7759\/cureus.39789.","DOI":"10.7759\/cureus.39789"},{"key":"3257_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e26701","volume":"10","author":"A Rauf","year":"2024","unstructured":"Rauf A, Wilairatana P, Joshi PB, Ahmad Z, Olatunde A, Hafeez N, et al. Revisiting luteolin: an updated review on its anticancer potential. Heliyon. 2024;10:e26701. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e26701.","journal-title":"Heliyon"},{"key":"3257_CR25","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2021.12452","volume":"21","author":"R Raina","year":"2021","unstructured":"Raina R, Pramodh S, Rais N, Haque S, Shafarin J, Bajbouj K, et al. Luteolin inhibits proliferation, triggers apoptosis and modulates Akt\/mTOR and MAP kinase pathways in HeLa cells. Oncol Lett. 2021;21:192. https:\/\/doi.org\/10.3892\/ol.2021.12452.","journal-title":"Oncol Lett"},{"key":"3257_CR26","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317692235","volume":"39","author":"NE El-Ashmawy","year":"2017","unstructured":"El-Ashmawy NE, Khedr NF, El-Bahrawy HA, Abo Mansour HE. Metformin augments doxorubicin cytotoxicity in mammary carcinoma through activation of adenosine monophosphate protein kinase pathway. Tumor Biol. 2017;39:1010428317692235. https:\/\/doi.org\/10.1177\/1010428317692235.","journal-title":"Tumor Biol"},{"key":"3257_CR27","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1177\/030089169307900408","volume":"79","author":"A-M Osman","year":"1993","unstructured":"Osman A-M, Ahmed MMS, Khayyal M-D, El-Merzabani MM. Hyperthermic potentiation of cisplatin cytotoxicity on solid Ehrlich carcinoma. Tumori. 1993;79:268\u201372. https:\/\/doi.org\/10.1177\/030089169307900408.","journal-title":"Tumori"},{"key":"3257_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.22924","volume":"35","author":"HH Atteia","year":"2021","unstructured":"Atteia HH, Arafa MH, Mohammad NS, Amin DM, Sakr AT. Thymoquinone upregulates miR-125a\u20105p, attenuates STAT3 activation, and potentiates doxorubicin antitumor activity in murine solid Ehrlich carcinoma. J Biochem Mol Toxicol. 2021;35:e22924. https:\/\/doi.org\/10.1002\/jbt.22924.","journal-title":"J Biochem Mol Toxicol"},{"key":"3257_CR29","doi-asserted-by":"publisher","first-page":"97","DOI":"10.21608\/0047700","volume":"47","author":"O Sayed Mohamed Ali","year":"2018","unstructured":"Sayed Mohamed Ali O, Abdel-Rahman Eldesoky N, Muhammad Salahuddin A, Mohamed Abdel-Aziz Eisa N. Atorvastatin ameliorates cisplatin-induced oxidative stress in Ehrlich ascites solid tumor-bearing mice: a prospective case control study. Al-Azhar Med J. 2018;47:97\u2013107. https:\/\/doi.org\/10.21608\/0047700.","journal-title":"Al-Azhar Med J"},{"key":"3257_CR30","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.3892\/or.2020.7781","volume":"44","author":"J Feng","year":"2020","unstructured":"Feng J, Zheng T, Hou Z, Lv C, Xue A, Han T, et al. Luteolin, an aryl hydrocarbon receptor ligand, suppresses tumor metastasis in vitro and in vivo. Oncol Rep. 2020;44:2231\u201340. https:\/\/doi.org\/10.3892\/or.2020.7781.","journal-title":"Oncol Rep"},{"key":"3257_CR31","doi-asserted-by":"publisher","first-page":"345","DOI":"10.2174\/1574886317666220429102445","volume":"18","author":"NE El-Ashmawy","year":"2023","unstructured":"El-Ashmawy NE, Khedr EG, El-Kady AY, Al-Ashmawy GM. Recombinant human lactoferrin augments epirubicin chemotherapy in solid Ehrlich carcinoma bearing mice. Curr Drug Saf. 2023;18:345\u201354. https:\/\/doi.org\/10.2174\/1574886317666220429102445.","journal-title":"Curr Drug Saf"},{"issue":"4","key":"3257_CR32","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/archotol.134.4.370","volume":"134","author":"M Cosetti","year":"2008","unstructured":"Cosetti M, Yu GP, Schantz SP. Five-year survival rates and time trends of laryngeal cancer in the US population. Arch Otolaryngol Head Neck Surg. 2008;134(4):370\u20139. https:\/\/doi.org\/10.1001\/archotol.134.4.370.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"3257_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3924-y","volume":"17","author":"C-H Chang","year":"2017","unstructured":"Chang C-H, Liu W-T, Hung H-C, Gean C-Y, Tsai H-M, Su C-L, et al. Synergistic inhibition of tumor growth by combination treatment with drugs against different subpopulations of glioblastoma cells. BMC Cancer. 2017;17:905. https:\/\/doi.org\/10.1186\/s12885-017-3924-y.","journal-title":"BMC Cancer"},{"key":"3257_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2014.00135","volume":"5","author":"GO Latunde-Dada","year":"2014","unstructured":"Latunde-Dada GO, Laftah AH, Masaratana P, McKie AT, Simpson RJ. Expression of ABCG2 (BCRP) in mouse models with enhanced erythropoiesis. Front Pharmacol. 2014;5:81005. https:\/\/doi.org\/10.3389\/fphar.2014.00135.","journal-title":"Front Pharmacol"},{"key":"3257_CR35","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00210-019-01803-2","volume":"393","author":"AE El-Sisi","year":"2020","unstructured":"El-Sisi AE, Sokar SS, Ibrahim HA, Abu-Risha SE. Enhanced anticancer activity of combined treatment of Imatinib and dipyridamole in solid Ehrlich carcinoma-bearing mice. Naunyn Schmiedebergs Arch Pharmacol. 2020;393:1113\u201329. https:\/\/doi.org\/10.1007\/s00210-019-01803-2.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"3257_CR36","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2013 \u2206\u2206CT method. Methods. 2001;25:402\u20138. https:\/\/doi.org\/10.1006\/meth.2001.1262.","journal-title":"Methods"},{"key":"3257_CR37","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","volume":"72","author":"MM Bradford","year":"1976","unstructured":"Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248\u201354. https:\/\/doi.org\/10.1016\/0003-2697(76)90527-3.","journal-title":"Anal Biochem"},{"key":"3257_CR38","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/0003-2697(81)90281-5","volume":"112","author":"WN Burnette","year":"1981","unstructured":"Burnette WN. Western blotting: electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem. 1981;112:195\u2013203. https:\/\/doi.org\/10.1016\/0003-2697(81)90281-5.","journal-title":"Anal Biochem"},{"key":"3257_CR39","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/jnci\/73.2.405","volume":"73","author":"H Shimada","year":"1984","unstructured":"Shimada H, Chatten J, Newton WA, Sachs N, Hamoudi AB, Chiba T, Marsden HB, Misugi K. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. JNCI. 1984;73:405\u201316. https:\/\/doi.org\/10.1093\/jnci\/73.2.405.","journal-title":"JNCI"},{"key":"3257_CR40","doi-asserted-by":"publisher","first-page":"7785","DOI":"10.1158\/1078-0432.ccr-05-0714","volume":"11","author":"K Ohuchida","year":"2005","unstructured":"Ohuchida K, Mizumoto K, Ishikawa N, Fujii K, Konomi H, Nagai E, Yamaguchi K, Tsuneyoshi M, Tanaka M. The role of S100A6 in pancreatic cancer development and its clinical implication as a diagnostic marker and therapeutic target. Clin Cancer Res. 2005;11:7785\u201393. https:\/\/doi.org\/10.1158\/1078-0432.ccr-05-0714.","journal-title":"Clin Cancer Res"},{"key":"3257_CR41","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.31557\/apjcp.2020.21.9.2561","volume":"21","author":"Y Roosta","year":"2020","unstructured":"Roosta Y, Sanaat Z, Nikanfar AR, Dolatkhah R, Fakhrjou A. Predictive value of CD44 for prognosis in patients with breast cancer. APJCP. 2020;21:2561\u20137. https:\/\/doi.org\/10.31557\/apjcp.2020.21.9.2561.","journal-title":"APJCP"},{"key":"3257_CR42","volume-title":"Discovering Statistics Using IBM SPSS Statistics","author":"A Field","year":"2018","unstructured":"Field A. Discovering Statistics Using IBM SPSS Statistics. 5th ed. SAGE Publications, North American Edition; 2018.","edition":"5th ed"},{"key":"3257_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2021.102793","volume":"70","author":"M Faruk","year":"2021","unstructured":"Faruk M. Breast cancer resistance to chemotherapy: when should we suspect it and how can we prevent it? Ann Med Surg (Lond). 2021;70:102793. https:\/\/doi.org\/10.1016\/j.amsu.2021.102793.","journal-title":"Ann Med Surg (Lond)"},{"key":"3257_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.121874","volume":"328","author":"SM Abdeljalil","year":"2023","unstructured":"Abdeljalil SM, Wahdan SA, Elghazaly H, Tolba MF. Insights into the therapeutic outcomes of trimetazidine\/doxorubicin combination in Ehrlich solid-phase carcinoma mouse tumor model. Life Sci. 2023;328:121874. https:\/\/doi.org\/10.1016\/j.lfs.2023.121874.","journal-title":"Life Sci"},{"key":"3257_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2019.108740","volume":"310","author":"NA Soliman","year":"2019","unstructured":"Soliman NA, Abd-Ellatif RN, ELSaadany AA, Shalaby SM, Bedeer AE. Luteolin and 5-fluorouracil act synergistically to induce cellular weapons in experimentally induced solid Ehrlich carcinoma: realistic role of P53; a guardian fights in a cellular battle. Chem Biol Interact. 2019;310:108740. https:\/\/doi.org\/10.1016\/j.cbi.2019.108740.","journal-title":"Chem Biol Interact"},{"key":"3257_CR46","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.4103\/jcrt.jcrt_1116_19","volume":"16","author":"KS Azab","year":"2020","unstructured":"Azab KS, El Fatih NM, El Tawill G, El Bakary NM. Pro-apoptotic and anti-neoplastic impact of luteolin on solid Ehrlich carcinoma-bearing mice exposed to gamma radiation. J Cancer Res Ther. 2020;16:1506\u201316. https:\/\/doi.org\/10.4103\/jcrt.jcrt_1116_19.","journal-title":"J Cancer Res Ther"},{"key":"3257_CR47","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.biopha.2018.10.169","volume":"109","author":"A Palko-\u0141abuz","year":"2019","unstructured":"Palko-\u0141abuz A, \u015aroda-Pomianek K, Weso\u0142owska O, Kostrzewa-Sus\u0142ow E, Uryga A, Michalak K. MDR reversal and pro-apoptotic effects of statins and statins combined with flavonoids in colon cancer cells. Biomed Pharmacother. 2019;109:1511\u201322. https:\/\/doi.org\/10.1016\/j.biopha.2018.10.169.","journal-title":"Biomed Pharmacother"},{"key":"3257_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27103227","volume":"27","author":"A Teisseyre","year":"2022","unstructured":"Teisseyre A, Chmielarz M, Uryga A, \u015aroda-Pomianek K, Palko-\u0141abuz A. Co-application of statin and flavonoids as an effective strategy to reduce the activity of voltage-gated potassium channels Kv1. 3 and induce apoptosis in human leukemic T cell line Jurkat. Molecules. 2022;27:3227. https:\/\/doi.org\/10.3390\/molecules27103227.","journal-title":"Molecules"},{"key":"3257_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-79892-w","volume":"11","author":"DH Kita","year":"2021","unstructured":"Kita DH, Guragossian N, Zattoni IF, Moure VR, Rego FG, Lusvarghi S, et al. Mechanistic basis of breast cancer resistance protein inhibition by new indeno [1, 2-b] indoles. Sci Rep. 2021;11:1788. https:\/\/doi.org\/10.1038\/s41598-020-79892-w.","journal-title":"Sci Rep"},{"key":"3257_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-89931-9","volume":"11","author":"W Yin","year":"2021","unstructured":"Yin W, Xiang D, Wang T, Zhang Y, Pham CV, Zhou S, et al. The inhibition of ABCB1\/MDR1 or ABCG2\/BCRP enables doxorubicin to eliminate liver cancer stem cells. Sci Rep. 2021;11:10791. https:\/\/doi.org\/10.1038\/s41598-021-89931-9.","journal-title":"Sci Rep"},{"key":"3257_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2022.106362","volume":"181","author":"F Deng","year":"2023","unstructured":"Deng F, Sj\u00f6stedt N, Santo M, Neuvonen M, Niemi M, Kidron H. Novel inhibitors of breast cancer resistance protein (BCRP, ABCG2) among marketed drugs. Eur J Pharm Sci. 2023;181:106362. https:\/\/doi.org\/10.1016\/j.ejps.2022.106362.","journal-title":"Eur J Pharm Sci"},{"key":"3257_CR52","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00210-015-1169-3","volume":"389","author":"B Atil","year":"2016","unstructured":"Atil B, Berger-Sieczkowski E, Bardy J, Werner M, Hohenegger M. In vitro and in vivo downregulation of the ATP binding cassette transporter B1 by the HMG-CoA reductase inhibitor simvastatin. Naunyn Schmiedebergs Arch Pharmacol. 2016;389:17\u201332. https:\/\/doi.org\/10.1007\/s00210-015-1169-3.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"3257_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25153364","volume":"25","author":"B MF Gon\u00e7alves","year":"2020","unstructured":"MF Gon\u00e7alves B, SP Cardoso D, U. Ferreira M-J. Overcoming multidrug resistance: flavonoid and terpenoid nitrogen-containing derivatives as ABC transporter modulators. Molecules. 2020;25:3364. https:\/\/doi.org\/10.3390\/molecules25153364.","journal-title":"Molecules"},{"key":"3257_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.19080\/ctoij.2021.18.555997","volume":"18","author":"D El Gueder","year":"2021","unstructured":"El Gueder D, Elahmar A, Dhaouefi Z, Toumia IB, Sioud F, Sassi A, et al. Luteolin induced apoptosis and blockage of P-glycoprotein in human sarcoma cell lines. CTOIJ. 2021;18:1\u20131. https:\/\/doi.org\/10.19080\/ctoij.2021.18.555997.","journal-title":"CTOIJ"},{"key":"3257_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24010391","volume":"24","author":"A Golonko","year":"2022","unstructured":"Golonko A, Olichwier AJ, Swislocka R, Szczerbinski L, Lewandowski W. Why do dietary flavonoids have a promising effect as enhancers of anthracyclines? Hydroxyl substituents, bioavailability and biological activity. Int J Mol Sci. 2022;24:391. https:\/\/doi.org\/10.3390\/ijms24010391.","journal-title":"Int J Mol Sci"},{"key":"3257_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20133338","volume":"20","author":"X Yuan","year":"2019","unstructured":"Yuan X, Xu D. Telomerase reverse transcriptase (TERT) in action: cross-talking with epigenetics. Int J Mol Sci. 2019;20:3338. https:\/\/doi.org\/10.3390\/ijms20133338.","journal-title":"Int J Mol Sci"},{"key":"3257_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-020-0252-9","volume":"6","author":"S-T Wang","year":"2020","unstructured":"Wang S-T, Huang S-W, Liu K-T, Lee T-Y, Shieh J-J, Wu C-Y. Atorvastatin-induced senescence of hepatocellular carcinoma is mediated by downregulation of hTERT through the suppression of the IL-6\/STAT3 pathway. Cell Death Dis. 2020;6:17. https:\/\/doi.org\/10.1038\/s41420-020-0252-9.","journal-title":"Cell Death Dis"},{"key":"3257_CR58","doi-asserted-by":"publisher","first-page":"3842","DOI":"10.3892\/ol.2019.10052","volume":"17","author":"L Huang","year":"2019","unstructured":"Huang L, Jin K, Lan H. Luteolin inhibits cell cycle progression and induces apoptosis of breast cancer cells through downregulation of human telomerase reverse transcriptase. Oncol Lett. 2019;17:3842\u201350. https:\/\/doi.org\/10.3892\/ol.2019.10052.","journal-title":"Oncol Lett"},{"key":"3257_CR59","doi-asserted-by":"publisher","first-page":"8616","DOI":"10.3390\/ijms23158616","volume":"23","author":"M Gerardo-Ram\u00edrez","year":"2022","unstructured":"Gerardo-Ram\u00edrez M, Keggenhoff FL, Giam V, Becker D, Groth M, Hartmann N, Straub BK, Morrison H, Galle PR, Marquardt JU. CD44 contributes to the regulation of MDR1 protein and doxorubicin chemoresistance in osteosarcoma. Int J Mol Sci. 2022;23:8616. https:\/\/doi.org\/10.3390\/ijms23158616.","journal-title":"Int J Mol Sci"},{"key":"3257_CR60","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/s12026-024-09493-6","volume":"72","author":"C de Sousa","year":"2024","unstructured":"de Sousa C, Eksteen C, Riedemann J, Engelbrecht A-M. Highlighting the role of CD44 in cervical cancer progression: immunotherapy\u2019s potential in inhibiting metastasis and chemoresistance. Immunol Res. 2024;72:592\u2013604. https:\/\/doi.org\/10.1007\/s12026-024-09493-6.","journal-title":"Immunol Res"},{"key":"3257_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26216452","volume":"26","author":"K-J Tsai","year":"2021","unstructured":"Tsai K-J, Tsai H-Y, Tsai C-C, Chen T-Y, Hsieh T-H, Chen C-L, et al. Luteolin inhibits breast cancer stemness and enhances chemosensitivity through the Nrf2-mediated pathway. Molecules. 2021;26:6452. https:\/\/doi.org\/10.3390\/molecules26216452.","journal-title":"Molecules"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03257-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03257-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03257-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T13:06:54Z","timestamp":1776344814000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03257-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":61,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["3257"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03257-y","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"175"}}